Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections
2018; American College of Physicians; Volume: 168; Issue: 7 Linguagem: Inglês
10.7326/l17-0705
ISSN1539-3704
Autores Tópico(s)Diabetes Treatment and Management
ResumoLetters3 April 2018Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin InjectionsThomas Haak, MDThomas Haak, MDDiabetes Center Mergentheim, Bad Mergentheim, Germany (T.H.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L17-0705 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We welcome Beck and colleagues' (1) trial assessing the effects of continuous glucose monitoring (CGM) in adults with type 2 diabetes receiving multiple daily injections of insulin. The results showed an adjusted mean reduction in hemoglobin A1c (HbA1c) of 0.3% in the CGM group, which was statistically significant but did not meet the investigators' definition of clinical significance (that is, a ≥ 0.4% difference between the intervention and control group according to the study protocol [2]). Furthermore, there was no significant difference in CGM-measured hypoglycemia or quality-of-life outcomes (1).The authors compared the results of their study with ...References1. Beck RW, Riddlesworth TD, Ruedy K, Ahmann A, Haller S, Kruger D, et al; DIAMOND Study Group. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med. 2017;167:365-74. [PMID: 28828487]. doi:10.7326/M16-2855 LinkGoogle Scholar2. Beck RW, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S, et al; DIAMOND Study Group. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA. 2017;317:371-8. [PMID: 28118453] doi:10.1001/jama.2016.19975 CrossrefMedlineGoogle Scholar3. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8:55-73. [PMID: 28000140] doi:10.1007/s13300-016-0223-6 CrossrefMedlineGoogle Scholar4. Ish-Shalom M, Wainstein J, Raz I, Mosenzon O. Improvement in glucose control in difficult-to-control patients with diabetes using a novel flash glucose monitoring device [Letter]. J Diabetes Sci Technol. 2016;10:1412-3. [PMID: 27277660] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Diabetes Center Mergentheim, Bad Mergentheim, Germany (T.H.)Disclosures: The author has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L17-0705. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoContinuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections Roy W. Beck , Tonya D. Riddlesworth , Katrina Ruedy , Andrew Ahmann , Stacie Haller , Davida Kruger , Janet B. McGill , William Polonsky , David Price , Stephen Aronoff , Ronnie Aronson , Elena Toschi , Craig Kollman , Richard Bergenstal , and Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections Roy W. Beck and Tonya D. Riddlesworth Metrics 3 April 2018Volume 168, Issue 7Page: 525-526KeywordsBody weightDisclosureGlucoseHbA1cHemoglobinHypoglycemiaInsulinPatientsResearch reporting guidelinesType 2 diabetes ePublished: 3 April 2018 Issue Published: 3 April 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Referência(s)